Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 34 Records) |
| Query Trace: Attention and CYP2D6[original query] |
|---|
| CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics. Journal of psychopharmacology (Oxford, England) 2011 Jul 25 (7): 908-14. Suzuki Yutaro, Sugai Takuro, Fukui Naoki, Watanabe Junzo, Ono Shin, Inoue Yoshimasa, Ozdemir Vural, Someya Toshiyu |
| Ecstasy (MDMA)-induced hyponatraemia is associated with genetic variants in CYP2D6 and COMT. Journal of psychopharmacology (Oxford, England) 2012 Mar 26 (3): 408-18. Aitchison Katherine J, Tsapakis Evangelia M, Huezo-Diaz Patricia, Kerwin Robert W, Forsling Mary L, Wolff K |
| Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics. Journal of clinical psychopharmacology 2014 Feb 34 (1): 139-42. Choi Chang-Ik, Bae Jung-Woo, Lee Yun-Jeong, Lee Hye-In, Jang Choon-Gon, Lee Seok-Yo |
| Inter-ethnic differences in genetic polymorphisms of xenobiotic-metabolizing enzymes (CYP1A1, CYP2D6, NAT1 and NAT2) in healthy populations: correlation with the functional in silico prediction. Molecular biology reports 2014 Sep 41 (9): 5735-43. Khlifi Rim, Ben Salah Ghada, Chakroun Amine, Hamza-Chaffai Amel, Rebai Ahm |
| Quantitative assessment of CYP2D6 polymorphisms and risk of Alzheimer's disease: a meta-analysis. Journal of the neurological sciences 2014 Aug 343 (1-2): 15-22. Lu Yu, Qin Xue, Li Shan, Zhang Xiaolian, He Yu, Peng Qiliu, Deng Yan, Wang Jian, Xie Li, Li Taijie, Zeng Zhi |
| Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability. Pharmacogenomics 2015 Aug 16 (13): 1513-20. Brown Jacob T, Bishop Jeffrey |
| The impact of the CYP2D6 gene polymorphism on the risk of pemphigoid. International journal of dermatology 2015 Jul . Rychlik-Sych Mariola, Bara?ska Ma?gorzata, Wojtczak Anna, Skr?tkowicz Jadwiga, ?ebrowska Agnieszka, Waszczykowska El?bie |
| CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial. Journal of clinical pharmacology 2015 Oct 55 (10): 1167-74. Fijal Bonnie A, Guo Yingying, Li Si G, Ahl Jonna, Goto Taro, Tanaka Yoko, Nisenbaum Laura K, Upadhyaya Himanshu |
| Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD. Clinical pharmacology and therapeutics 2015 Dec . Brown Jacob T, Abdel-Rahman Susan M, van Haandel Leon, Gaedigk Andrea, Lin Yvonne S, Leeder J Stev |
| Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach. British journal of clinical pharmacology 2016 Aug . Kim Min-Gul, Kim Yunjeong, Jeon Ji-Young, Kim Dal-S |
| Functional characterization of 22 novel CYP2D6 variants for the metabolism of Tamoxifen. The Journal of pharmacy and pharmacology 2016 Apr . Hu Xiao-Xia, Zhou Quan, Lan Tian, Huang Xiang-Xin, Liang Bing-Qing, Dai Da-Peng, Cai Jian-Ping, Hu Guo-X |
| Effect of CYP2D6 genetic polymorphism on the metabolism of citalopram in vitro. Drug metabolism and pharmacokinetics 2016 Jan . Hu Xiao-Xia, Yuan Ling-Jing, Fang Ping, Mao Yong-Hui, Zhan Yun-Yun, Li Xiang-Yu, Dai Da-Peng, Cai Jian-Ping, Hu Guo-X |
| In vitro assessment of 24 CYP2D6 allelic isoforms on the metabolism of methadone. Drug testing and analysis 2016 Mar . Su Ying, Zhan Yun-Yun, Wang Ben-Fu, Wang Si-Cong, Dai Da-Peng, Hu Guo-Xin, Lin Han, Lian Qing-Quan, Cai Jian-Pi |
| Development of a linear dual column HPLC-MS/MS method and clinical genetic evaluation for tramadol and its phase I and II metabolites in oral fluid. Archives of pharmacal research 2017 Dec . Yu Hyerim, Hong Seongkuk, Jeong Chul-Ho, Bae Jung-Woo, Lee Sooye |
| Individual variability in clinical effect and tolerability of opioid analgesics - Importance of drug interactions and pharmacogenetics. Scandinavian journal of pain 2017 10 17 193-200. Solhaug Vigdis, Molden Esp |
| Testing genetic modifiers of behavior and response to atomoxetine in autism spectrum disorder with ADHD. Journal of developmental and physical disabilities 2018 Jun 30 (3): 355-371. Barrie Elizabeth S, Pinsonneault Julia K, Sadee Wolfgang, Hollway Jill A, Handen Benjamin L, Smith Tristram, Arnold L Eugene, Butter Eric, Hansen-Kiss Emily, Herman Gail E, Aman Michael |
| The combined effect of CYP2D6 and DRD2 Taq1A polymorphisms on the antipsychotics daily doses and hospital stay duration in schizophrenia inpatients (observational naturalistic study). Psychiatria Danubina 2018 Jun 30 (2): 157-163. Kurylev Alexey A, Brodyansky Vadim M, Andreev Boris V, Kibitov Alexander O, Limankin Oleg V, Mosolov Sergey |
| Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy. Clinical pharmacology and therapeutics 2019 2 106 (1): 94-102. Brown Jacob T, Bishop Jeffrey R, Sangkuhl Katrin, Nurmi Erika L, Mueller Daniel J, Dinh Jean C, Gaedigk Andrea, Klein Teri E, Caudle Kelly E, McCracken James T, de Leon Jose, Leeder J Stev |
| Effects of 24 CYP2D6 variants found in Chinese population on the metabolism of clonidine in vitro. Chemico-biological interactions 2019 10 313 108840. Li Xiang-Yu, Hu Xiao-Xia, Yang Fang, Yuan Ling-Jing, Cai Jian-Ping, Hu Guo-X |
| CYP2D6 genotype may moderate measures of brain structure in methamphetamine users. Addiction biology 2020 8 26 (3): e12950. Dean Andy C, Nurmi Erika L, Morales Angelica M, Cho Arthur K, Seaman Lauren C, London Edythe |
| Pharmacogenetics of common SNP affecting drug metabolizing enzymes: comparison of allele frequencies between European and Malaysian/Singaporean. Drug metabolism and personalized therapy 2021 Mar 36 (3): 173-181. Bakar Nur Salwa |
| Pharmacogenetics of common SNP affecting drug metabolizing enzymes: comparison of allele frequencies between European and Malaysian/Singaporean. Drug metabolism and personalized therapy 2021 Mar . Bakar Nur Salwa |
| Influence of CYP2D6 gene polymorphisms on the pharmacokinetics of aripiprazole in healthy Chinese subjects. Pharmacogenomics 2021 2 22 (4): 213-223. Zhang Xiaodan, Liu Chengquan, Zhou Shuang, Xie Ran, He Xu, Wang Zhiqi, Yi Honghong, Shu You, Wang Zining, Hu Kun, Ma Lingyue, Cui Yimin, Zhao Xia, Xiang J |
| CYP450 2D6 and 2C19 genotypes in ADHD: not related with treatment resistance but with over-representation of 2C19 ultra-metabolizers. Drug metabolism and personalized therapy 2022 Feb . Kutuk Meryem Ozlem, Tufan Ali Evren, Topal Zehra, Acikbas Ufuk, Guler Gulen, Karakas Bahriye, Basaga Huveyda, Kilicaslan Fethiye, Altintas Ebru, Aka Yeliz, Kutuk Ozg |
| Study on the association between adverse drug reactions to opioids and gene polymorphisms: a case-case-control study. BMC pharmacology & toxicology 2023 11 24 (1): 64. Jing Yang, Ying-Zi Sun, Qun-Fang Li, Zheng Fu, Yu-Yao Guan, Chao Song, Lei Zhe |
| CYP2D6 and CYP2C19 Variant Coverage of Commercial Antidepressant Pharmacogenomic Testing Panels Available in Victoria, Australia. Genes 2023 10 14 (10): . Malcolm Forbes, Mal Hopwood, Chad A Bousm |
| [A precision medication study of atomoxetine in children with attention deficit hyperactivity disorder: CYP2D6 genetic testing and therapeutic drug monitoring]. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2023 1 25 (1): 98-103. Fu Di, Guo Hong-Li, Hu Ya-Hui, Chen Fe |
| Evaluation of SLC6A2 and CYP2D6 polymorphisms' effects on atomoxetine treatment in attention deficit and hyperactivity disorder. European journal of clinical pharmacology 2024 8 . Ismail Hasan Kole, P?nar Vural, Beste Yurdacan, Adem Alemdar, Caner Mut |
| Impact of Viloxazine Extended-Release Capsules (Qelbree) on Select Cytochrome P450 Enzyme Activity and Evaluation of CYP2D6 Genetic Polymorphisms on Viloxazine Pharmacokinetics. Clinical drug investigation 2024 4 . Zhao Wang, Tesfaye Liranso, Zulane Maldonado-Cruz, Alisa R Kosheleff, Azmi Nass |
| Dopamine Transporter and CYP2D6 Gene Relationships with Attention-Deficit/Hyperactivity Disorder Treatment Response in the Methylphenidate and Atomoxetine Crossover Study. Journal of child and adolescent psychopharmacology 2024 10 . Jeffrey R Bishop, Chuan Zhou, Andrea Gaedigk, Beth Krone, Rick Kittles, Edwin H Cook, Jeffrey H Newcorn, Mark A Ste |
- Page last reviewed:Feb 1, 2024
- Content source: